Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2518347123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Weihua Zeng und 53 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, DNA Methylation, Epigenome, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stand Up To Cancer-LUNGevity-American Lung Association, NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095.
- EarlyDiagnostics Inc., Agoura Hills, CA 91301.
- Department of Statistics, Stanford University, Stanford, CA 94305.
- Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095.
- Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095.
- Department of Radiological Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095.
ORCID-Profile: Weihua Zeng, Chun-Chi Liu, Shuo Li, Ran Hu, Qiao Liu, Benjamin Tran, Megumi Yokomizo, Shreya Gumate, Preeti Ahuja, Edward B Garon, Samuel W French, Carrie R Wong, Kevin G King, David S Lu, William Hsu, Vatche Agopian, Wing Hung Wong, Wenyuan Li, Xianghong Jasmine Zhou
Förderung
- Stand Up To Cancer-LUNGevity-American Lung Association
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
- NSF | NSF Graduate Research Fellowship Program (GRFP)
- HHS | NIH | National Human Genome Research Institute (NHGRI)
- NHGRI NIH HHS
- NSF (NSF)
- California Tobacco-Related Disease Research Program California Tobacco-Related Disease Research Program of the University of California
Zitieren
APA
Zeng, W., Liu, C. C., Li, S., Zhou, Y., Stackpole, M. L., Xiao, Y., Hu, R., Tang, C., Liu, Q., Zeng, W., Yeh, A., Melehy, A., Tran, B., Noor, Z., Yokomizo, M., Amara, D., Gumate, S., Ahuja, P., Li, D. Y., …, & Zhou, X. J. (2026). Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2518347123
Vancouver
Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, et al. Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2518347123
BibTeX
@article{Zeng2026,
author = {Zeng, Weihua and Liu, Chun-Chi and Li, Shuo and Zhou, Yonggang and Stackpole, Mary L and Xiao, Ying and Hu, Ran and Tang, Caitlin and Liu, Qiao and Zeng, Wanwen and Yeh, Angela and Melehy, Andrew and Tran, Benjamin and Noor, Zorawar and Yokomizo, Megumi and Amara, Dominic and Gumate, Shreya and Ahuja, Preeti and Li, David Yuanze and Zhao, Junting and Rose, Inga and Walker, Cattlena and Malik, Sadaf and Zhu, Yazhen and Tseng, Hsian-Rong and Garon, Edward B and French, Samuel W and Magyar, Clara E and Dry, Sarah M and Lajonchere, Clara M and Geschwind, Daniel and Choi, Gina and Saab, Sammy and Shetty, Akshay and Wong, Carrie R and King, Kevin G and Lu, David S and Raman, Steven S and Xiang, Xiyan and Shetty, Kirti and Mishra, Lopa and Memarzadeh, Sanaz and Liu, Yan and Alber, Frank and Hsu, William and Krysan, Kostyantyn and Dubinett, Steven M and Aberle, Denise R and Agopian, Vatche and Han, Steven-Huy B and Wong, Wing Hung and Ni, Xiaohui and Li, Wenyuan and Zhou, Xianghong Jasmine},
title = {Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2518347123}
}
EUVIMED